Identification of a Novel HIV-1 CRF55_01B/B Recombinant Isolate in Guangxi, China

Liang, Bingyu; Wei, Qiuyu; Yang, Yao; Yang, Yuan; Liu, Jie; Chu, Jiemei; Chen, Rongfeng; Liang, Hao; Li, Ye

doi:10.1089/aid.2019.0222

Cited by 7 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of this novel CRF ranged from 0.7% in Beijing to 14.6% in Guangzhou [27,28] and has increased in the past 5 years especially in South and East China [29]. Recently, more unusual CRFs derived from CRF55_01B isolates are being detected, which specified the complexity of HIV-1 strains [30]. Large cities may be the places where new recombinant strains would originate and spread.…”

Section: Discussionmentioning

confidence: 99%

HIV-1 Drug Resistance, Distribution of Subtypes, and Drug Resistance-Associated Mutations in Virologic Failure Individuals in Chengdu, Southwest China, 2014-2016

Chen

Liu

et al. 2020

BioMed Research International

Self Cite

View full text Add to dashboard Cite

The National Free Antiretroviral Therapy (ART) Program in China has initiated to provide ART to HIV-1 patients, which has acted as an efficient method to suppress viral replication and helps prevent onward transmissions. But the problems of HIV drug resistance (HIVDR) may also come along. There is little data on the prevalence of HIVDR in Chengdu, where the number of HIV/AIDS patients ranks first among provincial capitals. Therefore, epidemiological surveillance was conducted in this area. From 2014 to 2016, HIV/AIDS patients (15 years and older) who had received first-line ART for at least six months were enrolled. Demographic, behavioral information and medical history were recorded, and blood samples were collected for viral loads and immune cell count analyses. HIV-1 pol was obtained for HIV-1 subtypes and drug resistance-associated mutations (DRMs) among virologic failure patients. A total of 13,782 individuals were enrolled, and 481 samples were sequenced for subtypes and drug resistance analysis. Six subtypes were identified, among which CRF01_AE (54.3%) and CRF07_BC (41.6%) were the dominant subtypes, and CRF55_01B (0.4%) was detected in Chengdu for the first time. The prevalence of HIVDR in treatment-experienced patients was 1.8%, with 1.2% to nucleoside reverse transcriptase inhibitors (NRTIs), 1.7% to non-NRTIs (NNRTIs), and 0.14% to protease inhibitors (PIs). The leading DRMs observed in the study were M184I/V (59.59%) against NRTIs and K103N (37.55%) against NNRTIs. This study focused on the HIVDR surveillance among patients receiving treatment in Chengdu. The overall prevalence of HIVDR was relatively low among treated patients. These findings were believed to be contributed to an understanding of HIV-1 subtypes, HIVDR prevalence, and DRMs in Chengdu and thereby optimizing clinical management, prevention, and control of HIV.

show abstract

Section: Discussionmentioning

confidence: 99%

HIV-1 Drug Resistance, Distribution of Subtypes, and Drug Resistance-Associated Mutations in Virologic Failure Individuals in Chengdu, Southwest China, 2014-2016

Chen

Liu

et al. 2020

BioMed Research International

Self Cite

View full text Add to dashboard Cite

show abstract

“…The prevalence of CRF07_BC and CRF01_AE has increased since 2006 and they remain the dominant subtypes in China present in 31 provincial-level administrative divisions (PLADs) (1). In 2012, a study reported the HIV-1 CRF55_01B subtype, composed of CRF01_AE and subtype B, which possibly originated in men having sex with men (MSM) in Shenzhen (2). After its origin in Shenzhen, it spread rapidly to all cities in China (3).…”

Section: Introductionmentioning

confidence: 99%

“…In 2012, a study reported the HIV-1 CRF55_01B subtype, composed of CRF01_AE and subtype B, which possibly originated in men having sex with men (MSM) in Shenzhen ( 2 ). After its origin in Shenzhen, it spread rapidly to all cities in China ( 3 ). Various factors contribute to the spread and diversification of HIV-1 subtypes in China, including the emergence of more dating apps, the rapid development of the economy and means of transportation, and people moving to different parts of the country for employment.…”

Section: Introductionmentioning

confidence: 99%

Changing Proportions of HIV-1 Subtypes and Transmitted Drug Resistance Among Newly Diagnosed HIV/AIDS Individuals — China, 2015 and 2018

Hao¹,

Zheng²,

Gan³

et al. 2021

China CDC Weekly

View full text Add to dashboard Cite

Introduction: With the expansion of human immunodeficiency virus (HIV) antiretroviral therapy (ART), HIV drug resistance is becoming more and more serious. This study describes the changing prevalence of HIV-1 subtypes and transmitted drug resistance (TDR) among newly diagnosed individuals in China, 2015 and 2018.Methods: A total of 8,980 individuals in 2015 and 2018 from 31 provincial-level administrative divisions (PLADs) were enrolled in this study. Viral RNAs were amplified and sequenced using an in-house polymerase chain reaction (PCR) protocol. The Stanford HIV Drug Resistance Database (HIVdb) was used to predict susceptibility to 12 antiretroviral drugs.Results: The prevalence of TDR was not significantly increased over time. The prevalence of TDR was 3.8% and 4.4% in 2015 and 2018, respectively (P=0.13). The prevalence of CRF55_01B increased from 2.3% in 2015 to 3.9% in 2018 (P<0.001). The drug resistance prevalence of nonnucleoside reverse transcriptase inhibitors (NNRTI) increased from 2.4% in 2015 to 3.3% in 2018 (P<0.01). The prevalence of E138 (P<0.001), H221 (P=0.03), and V179 (P<0.001) mutations increased from 0.30%, 0.09%, and 0.70% in 2015 to 1.10%, 0.30%, and 1.70% in 2018, respectively.Conclusions: HIV drug resistance affects the effect of antiretroviral treatment, so the monitoring of HIV TDR should be strengthened to control the transmission of HIV drug resistance.

show abstract

The first third-generation HIV-1 circulating recombinant form (CRF114_0155) identified in central China

et al. 2021

View full text Add to dashboard Cite

Identification of a Novel HIV-1 CRF55_01B/B Recombinant Isolate in Guangxi, China

Cited by 7 publications

References 16 publications

HIV-1 Drug Resistance, Distribution of Subtypes, and Drug Resistance-Associated Mutations in Virologic Failure Individuals in Chengdu, Southwest China, 2014-2016

HIV-1 Drug Resistance, Distribution of Subtypes, and Drug Resistance-Associated Mutations in Virologic Failure Individuals in Chengdu, Southwest China, 2014-2016

Changing Proportions of HIV-1 Subtypes and Transmitted Drug Resistance Among Newly Diagnosed HIV/AIDS Individuals — China, 2015 and 2018

The first third-generation HIV-1 circulating recombinant form (CRF114_0155) identified in central China

Contact Info

Product

Resources

About